Age-related Macular Degeneration (AMD) is the #1 cause of vision impairment and severe vision loss among elderly people in the United States.
Our groundbreaking platform helps identify biomarker alterations associated with AMD risk years before vision loss begins.
This platform will be available as a CLIA-Certified Laboratory Service in Q1 2027
* Proof-of-concept study results. Performance characteristics to be validated in ongoing clinical studies.
The Paradigm Shift: Just as cholesterol testing predicts heart disease risk years before a heart attack, the Proactive Vision Analysis Platform analyzes blood biomarkers that may be associated with AMD development—during the critical window when prevention strategies may be most effective.
The Proactive Vision Analysis Platform provides risk assessment information that may indicate elevated AMD risk. This is not a diagnostic test.
A positive result indicates biomarker alterations that may be associated with elevated AMD risk, but does not confirm AMD diagnosis. A negative result does not rule out AMD presence or future development.
Results should be interpreted by your healthcare provider in the context of your medical history, family history, and clinical evaluation. Comprehensive eye examinations remain essential for retinal health monitoring. This platform is not a replacement for comprehensive eye examinations or existing AMD diagnostic modalities.
This test has not been cleared or approved by the US Food and Drug Administration. The platform is currently in clinical development and validation.
Discover how early AMD risk assessment can enable proactive vision care.